Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evalua
- Indication
- Schizophrenia
Other upcoming events for NYMXF
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Trial on the Effic
Patent ExpiryPatent/Exclusivity Expiry: SIRTURO
Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy an
Phase 3 ReadoutPhase 3 Topline: A Phase Ⅲ Randomized, Parallel-group, Placebo-controlled Trial to Assess the Efficacy, Safety of the
Phase 3 ReadoutPhase 3 Topline: A Multicenter, Randomized, Double-blind, Active-Controlled, Parallel, Phase Ⅲ Study to Evaluate the
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.